{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"16","upperLimit":"28","value":"24.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"}],"units":"Participants"}],"description":"Will be summarized descriptively using the Kaplan-Meier estimate. EFS will be censored if entospletinib is discontinued for other reasons (such as drug is no longer available).","dispersionType":"95% Confidence Interval","groups":[{"description":"The Outcome Measure was assessed in aggregate, combining participants from both phases of the study, as per the planned protocol.\n\nPhase 1, Dose 1 received entospletinib at Dose Level 1: 400 mg daily (200 mg twice daily) in combination with obinutuzumab during Dose Escalation phase of study.\n\nPhase 1, Dose 2 received entospletinib at Dose Level 2: 800 mg daily (400 mg twice daily) in combination with obinutuzumab during Dose Escalation phase of study.\n\nPhase 2, MTD: Received entospletinib at Maximum Tolerated Dose (MTD) in combination with obinutuzumab during Dose Expansion phase of study. The MTD was determined to be 800 mg daily (400 mg twice daily).","id":"OG000","title":"All Research Participants"}],"paramType":"MEDIAN","populationDescription":"Efficacy evaluable population: participants with CLL (Phase I/Phase II)","reportingStatus":"POSTED","timeFrame":"The interval between the date of first study treatment and the date of objective signs of disease recurrence, subsequent anti leukemic therapy, or death, whichever is first reported, assessed up to 45 months.","title":"Event Free Survival (EFS)","type":"SECONDARY","unitOfMeasure":"Months"}